EUVIMEDEUVIMED entdecken
Crossref

Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer

Koutaro Ono, Remi Murase, Natsumi Matsumoto, Yutaro Kubota, Hiroo Ishida, Ken-Ichi Fujita iD

Cancer Chemotherapy and Pharmacology · 2024

DOI: 10.1007/s00280-024-04649-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2024. Verfasst von Koutaro Ono und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, T…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Colorectal Neoplasms, Hand-Foot Syndrome, Vascular Endothelial Growth Factor A. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: JSPS Grant-in-Aid for Scientific Research (C).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsColorectal NeoplasmsHand-Foot SyndromeVascular Endothelial Growth Factor AChemokine CCL4AdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedEast Asian PeopleGenotypeJapanPhenylurea CompoundsPolymorphism, Single NucleotideProspective StudiesPyridinesRetrospective Studies

Stichwörter der Autor:innen

CCL4L2VEGFAHand-foot skin reactionProgression-free survivalRegorafenib

Substanzen

Antineoplastic AgentsPhenylurea CompoundsPyridinesregorafenibVascular Endothelial Growth Factor AVEGFA protein, humanChemokine CCL4

Autor:innen und Institutionen

  • Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.
  • Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.
  • Division of Medical Oncology, Showa University Northern Yokohama Hospital, 35-1 Chigasakichuo, Tsuzuki-ku, Yokohama, 224-8503, Japan.
  • Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan. k.fujita@med.showa-u.ac.jp.

ORCID-Profile: Ken-Ichi Fujita

Förderung

  • JSPS Grant-in-Aid for Scientific Research (C)

Zitieren

APA

Ono, K., Murase, R., Matsumoto, N., Kubota, Y., Ishida, H., & Fujita, K. I. (2024). Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-024-04649-5

Vancouver

Ono K, Murase R, Matsumoto N, Kubota Y, Ishida H, Fujita KI. Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer. Cancer Chemotherapy and Pharmacology. 2024. doi:10.1007/s00280-024-04649-5

BibTeX
@article{Ono2024,
  author = {Ono, Koutaro and Murase, Remi and Matsumoto, Natsumi and Kubota, Yutaro and Ishida, Hiroo and Fujita, Ken-Ichi},
  title = {Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2024},
  doi = {10.1007/s00280-024-04649-5}
}
Kostenlos starten →